Source:http://linkedlifedata.com/resource/pubmed/id/11516526
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2-3
|
| pubmed:dateCreated |
2001-8-22
|
| pubmed:abstractText |
Alteration in the testicular weight and various germ cell populations was studied in male mice treated with different doses (0.05, 0.25, 0.5, 1.0 and 2.0 mg/kg b. wt.) of teniposide (VM-26) at various post-treatment time periods. Treatment of mice with different doses of teniposide did not significantly alter the testicular weights, irrespective of the drug dose used. Flow-cytometric analysis of germ cells of the untreated control mice testes revealed four distinct DNA peaks corresponding to elongated spermatids (HC), round spermatids (1C), spermatogonia and non-germ cells (2C) and primary spermatocytes (4C). The region between 2C and 4C peaks represents cells that are actively synthesizing DNA (S-phase cells). Treatment of mice with different doses of teniposide resulted in a significant depletion in the relative percentage of spermatogonia from day 2 to 35 post-treatment depending on the drug dose. DNA-synthesizing, i.e. S-phase, cells declined significantly at day 1 post-treatment and continued to decline up to day 70 post-treatment for all the drug doses studied, except 2 mg/kg drug dose at day 28 post-treatment. A significant decline in the relative percentage of primary spermatocytes (4C) was observed at day 7 that continued up to day 70 post-treatment depending on the drug dose. Round spermatids (1C) declined significantly at day 21 post-treatment after administration of 0.25--2.0 mg/kg VM-26. The relative percentage of elongated spermatids showed a significant decline at day 28 after 1 and 2 mg/kg drug treatment. These alterations in different germ-cell populations are reflected in the various germ-cell ratios. The 4C:2C ratio showed a significant decline at day 7 and 14 post-treatment after 1 and 2 mg/kg VM-26 treatment, while the 1C:2C ratio declined significantly at day 21 post-treatment in the mice treated with 0.5 and 2.0 mg/kg of VM-26. 4C:S-phase and 1C:4C ratios increased significantly from day 1 to 70 post-treatment, depending on the drug dose. Our study demonstrates that the treatment of mice with low doses of VM-26 exerts cytotoxic effects on various germ-cell populations.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0300-483X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
21
|
| pubmed:volume |
163
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
163-74
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11516526-Animals,
pubmed-meshheading:11516526-Antineoplastic Agents,
pubmed-meshheading:11516526-Body Weight,
pubmed-meshheading:11516526-Diploidy,
pubmed-meshheading:11516526-Dose-Response Relationship, Drug,
pubmed-meshheading:11516526-Ethidium,
pubmed-meshheading:11516526-Flow Cytometry,
pubmed-meshheading:11516526-Fluorescent Dyes,
pubmed-meshheading:11516526-Injections, Intraperitoneal,
pubmed-meshheading:11516526-Male,
pubmed-meshheading:11516526-Mice,
pubmed-meshheading:11516526-Organ Size,
pubmed-meshheading:11516526-Sperm Count,
pubmed-meshheading:11516526-Spermatogenesis,
pubmed-meshheading:11516526-Spermatozoa,
pubmed-meshheading:11516526-Teniposide,
pubmed-meshheading:11516526-Testis,
pubmed-meshheading:11516526-Time Factors
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Evaluation of teniposide (VM-26)-induced toxicity on mouse spermatogenesis by flow cytometry.
|
| pubmed:affiliation |
Department of Radiobiology, Kasturba Medical College, Manipal-576 119, India.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|